|
Sep 23
|
Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
|
|
Aug 13
|
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
|
Jul 1
|
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 1
|
Solid Biosciences Joins the Russell 3000® Index
|
|
Jun 2
|
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth
|
|
May 15
|
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
|
|
May 7
|
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
|
|
Apr 3
|
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 2
|
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
|
|
Apr 1
|
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
|
|
Mar 28
|
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
|
|
Mar 27
|
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
|
|
Mar 13
|
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
|
|
Mar 7
|
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
|
|
Mar 6
|
Solid Biosciences to Participate at Upcoming Investor Conferences
|
|
Feb 29
|
14 Stocks With Heavy Insider Buying In 2024
|
|
Jan 15
|
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
|
|
Dec 9
|
While institutions invested in Solid Biosciences Inc. (NASDAQ:SLDB) benefited from last week's 68% gain, private equity firms stood to gain the most
|
|
Dec 8
|
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
|
|
Dec 7
|
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
|